NDI-010976 Chemical Properties

Boiling point:

779.0±70.0 °C(Predicted)

Density 

1.42±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO:75.0(Max Conc. mg/mL);131.66(Max Conc. mM)
DMF:10.0(Max Conc. mg/mL);17.56(Max Conc. mM)
Ethanol:3.0(Max Conc. mg/mL);5.27(Max Conc. mM)

form 

A crystalline solid

pka

3.66±0.10(Predicted)

color 

White to light yellow

NDI-010976 Usage And Synthesis

Description

ND-630 is an allosteric inhibitor of acetyl-CoA carboxylase (ACC) dimerization that inhibits ACC1 and ACC2 activity (IC₅₀s = 2.1 and 6.1 nM, respectively, for the human enzymes). It is selective for ACC over 101 enzymes, receptors, growth factors, transporters, and ion channels up to a concentration of 10 μM. ND-630 prevents dimerization of ACC by interacting within the phosphopeptide-acceptor and dimerization site. It reduces fatty acid synthesis (EC₅₀s = 66 and 9 nM in 10% FBS and serum-free media, respectively) and increases fatty acid oxidation in HepG2 cells. ND-630 reduces hepatic steatosis in a rat model of diet-induced obesity and in Zucker diabetic rats. It also improves insulin secretion stimulated by glucose and reduces hemoglobin A1c levels by 0.9% in Zucker diabetic rats.

Uses

Firsocostat or ND-630 (CAS# 1434635-54-7) is an inhibitor of acetyl-coA carboxylase and may favorably affect the morbidity and mortality associated with obesity, diabetes, and fatty liver disease from reduced hepatic steatosis, improved insulin sensitivity, and modulation of dyslipidemia.

NDI-010976(1434635-54-7)Related Product Information

• AC-262,356
• ND-646
• Remdesivir
• 2137975-08-5
• CU-CPT-8m
• CU-CPT-9a
• GW-870086